LGND — Ligand Pharmaceuticals Incorporated

Summary of Ligand's Q4 2025 Earnings Call

1. Key Financial Results and Metrics:

• Full-Year 2025 Performance:
  • Total GAAP revenue: $268 million (up from $167 million in 2024).
  • Core revenue (excluding Pelthos sale gain): $240 million, reflecting a 43% year-over-year growth.
  • Royalty revenue: $161 million, a 48% increase year-over-year.
  • Adjusted EPS: $8.13, up 42% year-over-year.
• Q4 2025 Performance:
  • Total revenue: $59.7 million (39% increase year-over-year).
  • Royalty revenue: $50.5 million (45% increase year-over-year).
  • Adjusted net income: $42.7 million or $2.02 per diluted share (up from $1.27 in Q4 2024).
  • Strong cash position: $734 million in cash and equivalents, over $1 billion in deployable capital.

2. Strategic Updates and Business Highlights:

• Ligand's royalty portfolio showed robust growth, driven by products like FILSPARI, Ohtuvayre, CAPVAXIVE, and Qarziba.
• Successful execution of a strategic merger involving Pelthos and Channel Therapeutics, enhancing equity and royalty value.
• Positive Phase 3 trial results for Palvella's QTORIN rapamycin, positioning it for potential FDA approval, with a significant market opportunity.
• Introduction of a systematic portfolio management strategy to enhance communication and investment opportunities with partners.
• Expansion of business development efforts and a deeper pipeline anticipated for 2026.

3. Forward Guidance and Outlook:

• 2026 guidance: Adjusted EPS of approximately $8 to $9 per share; royalty revenue expected to be between $200 million and $225 million (32% growth at midpoint).
• Total revenue forecast for 2026: $245 million to $285 million.
• Anticipated 23% compound annual growth rate in royalty receipts from 2025 to 2030, driven by existing commercial programs and new investments.

4. Bad News, Challenges, or Points of Concern:

• Delay in the FDA approval timeline for FILSPARI in FSGS, with a minimal contribution of $4 million expected for 2026.
• The complexity of the Tzield market due to its presymptomatic focus, which may limit growth despite potential blockbuster status.
• Overall, FSGS is expected to be a minor contributor in 2026, with significant contributions anticipated in later years.

5. Notable Q&A Insights:

• Management emphasized a proactive approach to portfolio management, identifying 5-10 opportunities for reinvigoration of older assets.
• Discussions on the potential of Tzield highlighted the challenges in accessing presymptomatic patients, which may affect its commercial growth.
• The company remains optimistic about the royalty financing market, which has doubled over the last five years, indicating strong demand regardless of broader market conditions.
• Management confirmed that the recent strong performance of Rylaze continues to position it as a key revenue driver, despite not being a primary focus in discussions.

Overall, Ligand's Q4 2025 earnings call reflected strong financial performance, strategic advancements, and a positive outlook, tempered by some challenges in regulatory approvals and market complexities.